Beginning with oncology, C4T is advancing multiple internal and partnered investigational degraders towards the clinic. Our balanced approach to target different cancers maximizes patient impact.
9 Additional Undisclosed Collaborator Programs in Discovery
The CFT7455 Phase 1/2 clinical trial is a two-part dose-escalation and expansion study evaluating CFT7455 across multiple hematologic malignancies. The Phase 1, first in human portion of the trial will explore CFT7455 as a single agent in patients with relapsed or refractory (R/R) multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL), and in parallel in combination with dexamethasone in R/R MM patients.